[May 27, 2015]

Research and Markets: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review 2015

Research and Markets (http://www.researchandmarkets.com/research/d4g3kt/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for RadiationToxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Aeolus Pharmaceuticals, Inc.
• Bolder Biotechnology, Inc.
• Cantex Pharmaceuticals, Inc.
• Cellerant Therapeutics, Inc.
• Cleveland BioLabs, Inc.
• Gamida Cell Ltd.
• Humanetics Corporation
• Meabco A/S
• NeoStem, Inc.
• Neumedicines Inc.
• Onconova Therapeutics, Inc.
• Piramal Enterprises Limited
• Pluristem Therapeutics Inc.
• Priaxon AG
• ProCertus BioPharm Inc.
• RDD Pharma Ltd.
• RxBio, Inc.
• Soligenix, Inc.
• Terapio Corporation
• Tonix Pharmaceuticals Holding Corp.
  

For more information visit http://www.researchandmarkets.com/research/d4g3kt/radiation

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527006706/en/

[ Back To TMCnet.com's Homepage ]